Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study by unknown
CORNEA
Systemic immunosuppression with mycophenolate mofetil
to prevent corneal graft rejection after high-risk penetrating
keratoplasty: a 2-year follow-up study
Jacek P. Szaflik1,2 & Joanna Major1,2 & Justyna Izdebska1,2 & Mieczysław Lao1,2 &
Jerzy Szaflik1,2
Received: 2 February 2015 /Accepted: 20 October 2015 /Published online: 9 November 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose In this study, we aimed to evaluate the efficacy and
safety of systemic immunosuppression with mycophenolate
mofetil (MMF) to prevent corneal graft rejection after high-
risk penetrating keratoplasty.
Methods One hundred and ninety-six consecutive patients
who underwent high-risk penetrating keratoplasty defined as
the presence of deep vascularization in more than two quad-
rants, keratouveitis, emergency keratoplasties, and
retransplantations were enrolled in the study. Ninety-eight
prospectively followed up patients were treated with MMF
[with dose adjustment based on mycophenolic acid (MPA)
serum concentration], and 98 patients were in the non–
MMF-treated retrospectively assessed control group.
Results During a mean of 24 months of observation, immune
reactions occurred in eight cases (8%) and graft rejection with
subsequent graft failure occurred in three cases (3 %) in the
MMF group. In the control group, graft rejection occurred in
76 cases (78 %) and failure due to graft rejection occurred in
30 cases (31 %). Kaplan–Meier analysis demonstrated that
93 % of the grafts in the MMF-treated group and 47 % in
the control group showed no immune rejection (p<0.01,
log-rank test) after a year. Cox regression analysis proved that
MMF treatment decreased the risk of graft rejection 11 times
(RR=11, 95.0 % CI 4.8–25, p<0.0001). Among 98 MMF-
treated patients, 13 had gastric discomfort, three developed
leucopenia, and two had anemia that resolved after MMF dose
reduction.
Conclusions MMF treatment after high risk penetrating kera-
toplasty is safe and reduces the incidence of immune graft
rejection and graft failure. Side effects were rare and reversible
in all but one case.
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Introduction
The cornea is the most frequently transplanted tissue, with the
exception of blood transfusions. The overall survival rate of
low-risk corneal grafts reaches 85 %–90 % in 10 years of
follow-up [1–3]. However, despite the progress in medical
treatment and microsurgical procedures, penetrating kerato-
plasty in high-risk patients (high-risk penetrating keratoplasty
[HRPK]) remains a challenging procedure due to the risk of
irreversible allograft rejection. Allograft rejection occurs in
40–70 % of these patients during the first year after transplan-
tation [4–6], and immune graft rejection is the main cause of
corneal graft failure and loss of its transparency [7].
The use of cyclosporine A (CsA) is limited due to its tox-
icity and the risk of neocancerogenesis. Side effects such as
nephrotoxicity, hepatotoxicity, hypertension, altered glucose
metabolism, and gingival hyperplasia occur in up to 40 % of
patients [8, 9], but probably the most threatening complication
is the increased incidence of malignancy (cancers, lympho-
mas) [10, 11]. Reis et al. [12] and Birnbaum et al. [9] showed
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that mycophenolate mofetil (MMF) and CsA were equally
effective and MMF treatment had a favorable safety profile,
as the complications associated with MMF administration
have mainly included gastrointestinal and hematologic prob-
lems (e.g., leucopenia, anemia), all of which are reversible
after cessation of the drug’s dosage [13–15].
The aim of our study was to evaluate the efficacy and safety
of systemic immunosuppression with MMF in the prevention
of corneal graft rejection after HRPK with 2 years of follow-
up.
Material and methods
Patients, treatment schedule, and follow-up
A total of 196 patients were included in the analysis. All
patients underwent HRPK in the University Ophthalmic
Hospital in Warsaw. Ninety-eight consecutive patients were
treated with MMF and prospectively followed up. The control
group included 98 consecutive patients assessed retrospective-
ly. In 2009, results of a multicenter, prospective and random-
ized clinical study concerning the efficacy of mycophenolate
mofetil after high-risk corneal transplantation were published
[16]. Recruitment for the study’s control group was prema-
turely stopped due to a statistically significant difference be-
tween treated patients and the non-MMF-treated control group
(in favor of the group treated with MMF). That is why the
control group was assessed retrospectively in our study; we
found it unethical not to administer effective therapy [16].
Informed consents were obtained, and the local bioethical
committee approved the study. We defined high-risk kerato-
plasty as retransplanted keratoplasties, emergency transplan-
tations in case of corneal perforation due to bacterial infec-
tions, presence of deep vascularization in three or four quad-
rants, and transplantation in patients with keratouveitis
(Table 1). Exclusion criteria included perforation due to un-
known cause, viral or fungal corneal infections, and glaucoma
diagnosed prior to the surgery. The indications for corneal
transplantation are listed in Table 2.
HLA and ABO blood group antigen matching had not been
performed before the surgery.
All donor corneas were stored in Eusol GS medium at 4 °C
(mean time of storage, 5 days). The mean endothelial cell
density of donor corneal button was 2400 cells/mm2 (1700-
3000 cells/mm2).
All patients underwent penetrating keratoplasty or pene-
trating keratoplasty with extracapsular cataract extraction
(Table 3). The mean diameter of the donor corneal discs was
8.0±0.5 mm, 0.5 mm larger than the diameter of the recipient
bed. In cases of emergency keratoplasties, interrupted 10-0
nylon sutures were used; in other cases, a combination of
interrupted and continuous 10-0 nylon sutures was applied.
All knots were buried in the peripheral host cornea. Directly
after surgery, all patients received antibiotic eye drops (fluo-
roquinolone), and subconjunctival injection of dexametha-
sone was administered.
Patient data are listed in Tables 3 and 4.
Group 1 was prospectively followed up and received my-
cophenolate mofetil (CellCept®, Roche Pharma AG,
Grenzach-Wyhlen, Germany), according to a set protocol.
All group 1 patients were examined by the transplantologist,
and a thorough assessment was conducted comprising the
patient’s history of peptic ulcer, malignancy, and chronic in-
fections; blood pressure measurement; and laboratory tests,
including complete blood cell count, serum creatinine, and
liver functions. Afterwards, systemic immunosuppression
was introduced. A day before surgery,MMFwas administered
at an initial dose of 2×1000 mg. On the day of surgery and for
2 days after, the patients received methylprednisolone sodium
succinate intravenously (1st day, 500 mg; 2nd day, 250 mg;
3rd day, 250 mg). On the fourth day, methylprednisolone was
administered orally (0.4 mg/kg daily). MPA serum concentra-
tion was measured on the seventh day after surgery (a predose
MPA serum concentration reached about 2 μg/ml and nomore
than 5 μg/ml). Methylprednisolone was tapered during the
first month after surgery to reach the lowest possible dose of
5–10 mg daily, and was discontinued after 11 months. A
month after the operation, MMF was also tapered to 2×
500 mg, after 6 months to 2×250 mg, and a year after surgery
MMF was discontinued. Since immunosuppressive therapy
may activate viral infections (e.g., herpes simplex virus, cyto-
megalovirus, human papillomavirus) and induce atypical in-
fections (Pneumocystis jirovecii), prophylaxis for 6 months
with acyclovir (4×400 mg daily) and co-trimazole (480 mg
twice daily for 3 months tapered to 480 mg daily) was intro-
duced. Apart from systemic treatment, topical steroid drops
were administered (loteprednol etabonate).
Group 2 consisted of 98 consecutive patients assessed ret-
rospectively with no systemic immunosuppressive therapy
administered. On the day of the surgery and in the next 2 days
after surgery, the patients received methylprednisolone sodi-
um succinate intravenously (500 mg once daily). On the
fourth day, the patients received methylprednisolone
(1 mg/kg). The mean dose of methylprednisolone after a
month was 0.5 mg/ kg daily; after 2 months, it was 0.3 mg/kg
daily; and after 6 months, it was 5–10 mg daily.
Patients in both groups received (from the first day
after surgery) topical antibiotic drops or ointment
(fluoroquinolone) until epithelial healing was complete, and
afterwards they received topical steroid for a year or longer,
depending on their response, until all sutures were removed
(loteprednol was administered in the MMF group and dexa-
methasone in the control groups four to six times daily for
2 months, three times daily until the sixth month, and two
times daily thereafter for 6 months or longer).
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Postoperative examinations were performed each day during
the first week after surgery, and then on the following schedule:
1, 3, 6, 12, and 24 months after surgery. The examination in-
cluded visual acuity for distance and near vision, intraocular
pressure measurement, and slit lamp examination. Apart from
the ophthalmic examination, each patient was examined by the
transplantologist. Side effects (gastrointestinal, hematologic)
and MPA plasma concentration were closely monitored.
Predose MPA plasma concentration was measured a week after
surgery, a month after surgery, 3 months after surgery, and each
time the dosage of MMF was changed (during the follow-up
time, an average of three measurements were taken).
The main outcomes of the study were occurrence of im-
mune graft rejection and graft survival. Immune reactions
were diagnosed on the basis of a patient’s complaints (redness,
discomfort, pain, worse visual acuity, photophobia, lacrima-
tion) and slit lamp examination findings, such as endothelial
precipitates, Khodadoust line, noninfectious subepithelial in-
filtrates, and stromal edema [17]. In case of immune graft
rejection, patients in both groups were treated with topical
dexamethasone drops every hour and with ointment at bed-
time. In case of severe reactions (more than five keratic pre-
cipitates, inflammatory cells in stroma not due to infection,
endothelial rejection line, stromal oedema, cells in aqueous
humor) [18], the patients (group 1 and 2) were admitted to
hospital and treated with intravenous methylprednisolone so-
dium succinate (500 mg for 3 days) and oral methylpredniso-
lone acetate (1 mg/kg) afterwards, in addition to topical treat-
ment as mentioned above. Patients in group 1 also had their
MMF dosage increased to 2×1000 mg daily.
Clear graft survival was determined when there was no
opacity in the 4-mm central zone of the corneal button. Graft
failure was diagnosed with the presence of irreversible corneal
edema and graft opacity.
Statistical analysis
Statistical analysis was carried out using R statistical software.
Groups 1 and 2 were compared using Student’s t-test (pa-
tient age, visual acuity, graft diameter, follow-up time) and
Mann–Whitney U test (endothelial cell density, donor age,
donor tissue storage time). Chi-squared test was performed
to compare surgical procedures employed. The Kaplan–
Meier estimator was used to establish clear graft survival
and rejection-free interval. Statistical significance was deter-
mined using the log-rank test. For all tests, a p value below
0.05 was considered statistically significant. Proportional
Table 1 Indications for HRPK
(Fisher’s exact test: p=0.247; no
statistical difference)
Diagnosis Group 1 (MMF) Group 2 (control) Total
3 or 4 quadrants with deep vascularization (n) 12 12 24
3 or 4 quadrants of retransplanted corneal button
with deep vascularization
20 24 44
Emergency transplantations (n) 30 40 70
Retransplantations (n) 31 20 51
Active recurrent or chronic uveitis (n) 5 2 7
Table 2 Indication for the





Corneal opacity and neovascularization due to
severe dry eye syndrome
1 2 3
Alkali burn 7 9 16
Trauma ulcer 4 1 5
Graft failure due to graft rejection 35 30 65
Graft failure due to nonhealing epithelial defect 4 3 11
Graft failure due to corneal melt 6 5 12
Graft failure due to bacterial corneal ulcer 6 6 14
Acute perforation of non-infectious corneal ulceration 3 4 7
Refractory bacterial keratitis 5 7 12
Acute perforation of corneal ulcer 22 29 51
Keratouveitis of idiopathic etiology 5 2 7
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hazards model (Cox regression) was used to establish risk
factors of graft rejection.
Results
Demography
One hundred and ninety-six consecutive patients (103 women
and 93 men, aged 21–92 years) were enrolled in the study. Of
these, 98 were prospectively followed up and treated with
systemic immunosuppression with MMF (group 1), and 98
were included in a retrospective control group with no system-
ic immunosuppression with MMF administered (group 2).
None of the patients were lost for the follow-up. Mean
follow-up timewas 56±31weeks in group 1 and 51±39weeks
in group 2.
There was no statistically significant difference between
the two groups regarding preoperative best correct visual acu-
ity, recipient age, donor age, quality of the donor corneal disc,
tissue storage time, preoperative graft endothelial cell density,
graft diameter, or the type of surgery performed.
Patient data are shown in Tables 1, 2, 3 and 4.
Efficacy
The mean time of observation was 95 weeks (94±21 weeks in
group 1 and 97±18 weeks in group 2). At this time, 84 of all
196 patients (43 %) experienced immune graft rejection, and
graft failure due to immune reactions occurred in 33 patients
(almost 17 %). Graft failure due to other causes occurred in
only 10 cases (5 %).
In group 1, immune reactions occurred in eight cases (8 %)
during and despite MMF treatment, and five of them were
reversible; in four cases (50 %), the rejection was treated as
severe reaction. Graft failure due to graft rejection occurred in
three cases (3 % of patients). Another six cases (6 %) experi-
enced graft failures due to other causes (nonhealing, persistent
erosions, glaucoma, or infection). Regarding the underlying
diagnosis: 50 % of the rejected emergency and repeated trans-
plants failed (lost transparency). In case of patients with
retransplanted vascularized corneas, none of the rejected
grafts lost transparency and none of the patients with the
keratouveitis rejected the graft (Tables 5 and 6).
In group 2, graft rejection occurred in 76 cases (77 %); in
15 of these cases, there was more than one episode of immune
reaction during the follow-up, and in 33 cases (43 %) the
rejection was severe. In 45 of the 76 cases, the reaction was
reversible. Failure due to graft rejection occurred in 30 cases,
and other causes for graft failure (nonhealing, persistent ero-
sions, glaucoma) occurred in four cases. Regarding the under-
lying diagnosis: 50 % of the rejected emergency grafts, 40 %
of the repeated transplants and 44 % retransplants with
vascularized corneal bed failed (lost transparency). None of
the grafts of patients with uveitis and immune reaction after
the transplantation failed (Tables 5 and 6).
Efficacy data are shown in Tables 5 and 6.
According to Kaplan–Meier curves (Fig. 1), after
12 months of therapy, grafts without immune rejections
accounted for 93 % of group 1 (MMF treated) and 47 % of
group 2 (control group) (p<0.01 in log-rank test). Cox regres-
sion analysis proved that MMF treatment decreased the risk of
graft rejection 11 times (95.0 % CI 4.8–25, p<0.0001).
Furthermore, the other group characteristics (recipient’s age
and sex, quality of the transplanted tissue, endothelial cell
Table 3 Type of surgery (χ2=
1.42, p=0,54; no statistical
difference)
Group 1 (MMF) Group 2 (control) Total





cataract extraction+intraocular lens implantation (n)
25 24 49
Table 4 Patient data
Group 1 (MMF) Group 2 (control) Total p value
Patients (n) 98 98 196
Male/female (n) 51/47 42/56 93/103 0.253 (ns)*
Age (mean±SD) 58±16 56±16 0.508 (ns)**
Follow-up (days) 394.9±214 353.7±270 0.238 (ns)***
ns, no statistical difference.
* Pearson’s χ2 test; **Mann–Whitney U test; *** Student’s t test.
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count of the donor tissue, diameter of the corneal but-
ton, donor age, time of storage, diagnosis, type of the
surgery) included in the model had no effect on graft
rejection. This indicates that the diminished risk of an
immune response observed in group 1 (MMF treated)
was a result of the therapy, and other factors that char-
acterized the treatment group (recipient’s age and sex,
quality of the transplanted tissue, endothelial cell count
of the donor tissue, diameter of the corneal button, do-
nor age, time of storage, diagnosis, type of the surgery)
did not influence the result.
The Kaplan–Meier plot illustrating clear graft survival
(Fig. 2) shows that after a year of therapy, only 2 % of
grafts failed in the MMF group compared to 19 % in
the control group.
Safety
In the MMF group, 13 patients (13.5 %) complained of gas-
trointestinal disturbances, but immunosuppressive treatment
only had to be stopped in one case with refractive diarrhea.
In other cases, proton pump inhibitors or MMF enteric-coated
mycophenolate sodiumwere administered, and the discomfort
subsided.
There were also two cases of anemia and three of leucope-
nia, which resolved after reduction of the MMF dosage.
Discussion
There are three main immunologic risk factors for graft rejec-
tion: vascularization, inflammation, and previous graft rejection
[19, 20], which we accounted for in the inclusion criteria of our
study. In the Collaborative Corneal Transplantation Studies
(CCTS) high-risk keratoplasty was defined as having two or
more quadrants with deep stromal vessels; if corneas had vas-
cularization in four quadrants, the risk for immune graft rejec-
tion doubled [4]. These findings were confirmed in other stud-
ies. The depth and extent of vessels seem to be critical factors
for corneal graft survival (the more vessels, the higher risk for
graft rejection) [4, 20, 21]. Active inflammation at the time of
surgery is also a risk factor for corneal graft rejection and graft
failure [4, 5, 7] as well as regrafting, especially if the failure was
the result of immune graft rejection [4, 6, 21].
Topical application of corticosteroids is the gold standard
after low-risk keratoplasties because it provides effective im-
munosuppression and good anterior chamber penetration [22].
But the impact of topical steroids is often insufficient in
preventing graft rejection in high-risk patients. These proce-
dures require an increased use of the eye drops, which can
cause side effects such as cataract, glaucoma, or delayed wound
healing. These impediments explain why the search for optimal
treatment schedules for such patients remains ongoing.
To our knowledge, only two immunosuppressives are rou-
tinely used after high-risk keratoplasties: CsA and MMF.
Table 5 Efficacy
Group 1 (MMF) Group 2 (control) p value*
Graft rejection (n) 8 76 < 0.01
Graft failure due to graft rejection (n) 3 30 < 0.01
Graft failure due to other causes (n) 6 4
Nonhealing, persistent epithelial defects (n) 4 3
Glaucoma decompensation (n) 1 1
Infection (n) 1 0
* log rank test
Table 6 Rejected and failed
grafts based on the underlying
diagnosis









3 or 4 quadrants with deep vascularization
(n=12)
0 0 (0 %) 8 0 (0 %)
3 or 4 quadrants of retransplanted corneal
button with deep vascularization (n=20)
2 0 (0 %) 18 8 (44 %)
Emergency transplantations (n=30) 4 2 (50 %) 20 10 (50 %)
Retransplantations (n=31) 2 1 (50 %) 29 12 (41 %)
Active recurrent or chronic uveitis (n=5) 0 0 (0 %) 1 0 (0 %)
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CsA was introduced in ophthalmology in the mid-1980s,
and its use in ophthalmology is well established. Many pub-
lications report good effects from CsA use after HRPK, but
some report no benefits. In a meta-analysis of randomized
controlled trials with two studies on CsA versus placebo,
pooled analysis of clear graft survival showed no differences
between the two groups [23]. CsA may be the cause of sig-
nificant side effects, including hypertension, nephrotoxicity,
neurotoxicity, and malignancies [10, 11, 24, 25].
In a prospective, randomized, multicenter study conducted
by Birnbaum et al. [9], MMF was administered for 6 months
after high-risk keratoplasty. In this study, HLA loci were
typed, but the HLA matching was not performed. In the
MMF group (n=50), there were eight cases (16 %) of graft
rejections, and two of them were irreversible; whereas, in the
control group (n=37), there were 12 cases (32 %) of immune
graft rejection and seven were irreversible. The difference
between the groups in graft rejection episodes was statistically
significant (p=0.044). It is worth mentioning that all rejection
episodes in the MMF group occurred after cessation of MMF.
In our study, the patients were treated with MMF at full
dosage (1000 mg twice daily) for about a month. Under opti-
mal conditions, the dosage was tapered to 750 or 500 mg
twice daily after a month and continued for the next 5 months.
During the seventh month, the dosage was reduced to 2 x
250 mg daily, and MMF was discontinued after 12 months.
In control group 2, the doses of methylprednisolone were
higher than in the MMF group (1 mg/kg vs. 0.4 mg/kg at
the beginning, 0.5 mg/kg vs. 5–10 mg daily after 2 months,
0.3 mg/kg vs. 5–10 mg daily after 3 months). The doses in
both groups equaled after 6 months. It should also be stressed
that most of the patients in group 2 (76 of 98, 77,6 %) did not
follow the scheme, as when graft rejection occurred, the dos-
age of methylprednisolone was increased to 1 mg/kg daily, so
mean doses of methylprednisolone were actually higher.
We also observed statistically significant differences in im-
mune graft rejection and graft failure between the MMF and
control groups (p<0.01). There were eight episodes (8 %) of
graft rejection in the MMF-treated group (n=98), with three
irreversible cases; in the control group (n=98), there were 75
(almost 77 %) patients with graft rejection, and 30 of them
eventually had graft failure. In the present study, about 40 %
of grafts in both groups had irreversible immune rejection.
Compared with the study of Birnbaum et al. [9], our groups
were larger, which may explain why the effect of MMF treat-
ment was even more pronounced.
Taking into account the underlying diagnosis, the same
percentage of rejected emergency grafts in both groups failed
(50 % of rejected MMF-treated and MMF-non-treated grafts
lost transparency). These results are comparable to other stud-
ies, as other researchers found 25–62 % of emergency graft
lost their transparency [26, 27].
As far as retransplantations are concerned, respectively,
50 % of grafts (one patient) in group 1 and 40 % of grafts
(12 patients) in group 2 failed. The literature shows that about
33 to 46 % of repeated grafts fail in 2 years of follow-up [26,
28–30].
Forty-four percent of neovascularized regrafts failed in the
control group, which is less than other researchers found (50-
83 %) [26, 27].
The results are summarized in Tables 5 and 6. Emergency
transplants and retransplantations seem to be high-risk factors
for permanent loss of graft transparency. The main side effects
in our MMF group (n=98) were gastrointestinal disorders in
13 cases (13 %) and hematologic changes (anemia, leucope-
nia) in five cases (5 %). Apart from one patient with refractory
diarrhea, all side effects were well tolerated and reversible. In
the study of Birnbaum et al. [16], out of 57 MMF-treated
patients, 36 (63 %) suffered from side effects, but the authors
noted that they were probably the effect of systemic
Fig. 1 Kaplan-Meier survival curve concerning immune rejection free
graft survival (log-rank test: p<0.01)
Fig. 2 Kaplan-Meier survival curve concerning clear graft survival (log-
rank test: p<0.01)
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immunosuppression with MMF in only 24 cases (42 %). In
that study, 15 patients (26 %) suffered from gastrointestinal
disturbances; in one case, the MMF therapy was stopped,
eight patients (14 %) developed infections, and one had ane-
mia. The authors also reported two cases of malignancies (3
and 5 months after surgery) [16]. In the Reis et al. [12] study,
Hodgkin’s lymphoma was diagnosed in the MMF group a
month after surgery. Cancerogenesis due to MMF use cannot
be excluded, but it seems unlikely. In 2005, a study based on
data collected on almost 7000 patients in the Organ
Procurement and Transplantation Network, United Network
for Organ Sharing and Collaborative Transplant Study registry
showed that there was no statistically significant difference
between MMF-treated and non–MMF-treated de novo renal
transplant recipients in 3 years of follow-up study for the
development of lymphomas (p=0.999) and other malignan-
cies (p=0.088) [15]. MMF is considered less active in
cancerogenesis than CsA or tacrolimus, and treatment of less
than 6 months seems too short to induce neoplastic disease. It
is more probable that the patients were asymptomatic prior to
keratoplasty. Nevertheless, other studies reported more side
effects than we observed. Because MMF treatment seems
rather safe, most authors do not monitor MPA serum level.
Taking into account each patient’s variability and the dynamic
relationship between the pharmacokinetics and pharmacody-
namics of the drug, we believe that monitoring of MPA serum
concentration should be mandatory, because it helps to avoid
exceeding safe drug levels and permits individual dosage
adjustment.
In conclusion, our study provides further evidence to con-
firm that systemic MMF treatment after HRPK considerably
reduces the number of patients with immune graft rejection
and graft failure. Most of the side effects are transient or re-
versible after adjusting the therapy, and the treatment is rela-
tively safe. Since it was previously reported that pharmaco-
logically induced immune tolerance may decrease after a cer-
tain time and MMF treatment may be insufficient, long-term
graft survival studies need to be conducted [31].
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